Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 11 Nov 2026
Standard addition

Gene therapy for hemoglobinopathies.

Gene therapy cures sickle cell and thalassemia in the short term, though long-term safety monitoring continues.

The review assessed gene-modified hematopoietic stem-cell therapy for hemoglobinopathies. Two commercial products show strong short- and intermediate-term efficacy, while conditioning toxicity, fertility, organ outcomes, and malignancy risk require longer follow-up.

What the study was

Study design
Narrative clinical review
Population
Patients with sickle cell disease or transfusion-dependent thalassemia
Category
Treatment Innovation
Maturity
Validated
Journal
Seminars in hematology

Why it surfaced

The review addresses transformative treatment for high-unmet-need disorders, but long-term safety evidence remains incomplete

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.